APG-2449 in Patients With Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 40
Summary
- Conditions
- Advanced Solid Cancer
- Esophageal Cancer
- Malignant (Pleural) Mesothelioma
- Non -Small Cell Lung Cancer
- Ovarian Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: Beginning with 150 mg dose level, and escalating to 300mg, 450mg, 600mg, 750mg, and 900mg dose level sequentially under "3+3" designMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03917043
- Collaborators
- Suzhou Yasheng Pharmaceutical Co., Ltd.
- Investigators
- Principal Investigator: Li Zhang, Professor Sun Yat-sen University